wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q36059792-664C598C-10B4-4906-AEF1-4F1ADAD3EE15
Q36059792-664C598C-10B4-4906-AEF1-4F1ADAD3EE15
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36059792-664C598C-10B4-4906-AEF1-4F1ADAD3EE15
Oxopyrido[2,3-d]pyrimidines as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors
P2860
Q36059792-664C598C-10B4-4906-AEF1-4F1ADAD3EE15
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36059792-664C598C-10B4-4906-AEF1-4F1ADAD3EE15
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
c278d4acf5f9bf4f774d02c84bcb1a3237e28bc5
P2860
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.